An international summit on maximising the translation of biomedical research into economic and societal benefit. With several of the world’s leading research universities and top academic and financial talent, Britain appears well positioned to lead the world in the development and commercialisation of major biomedical advances. But despite these huge structural advantages, British biotech firms attract only 4% of the world’s biotech capital in comparison with 72% in the United States. What could Britain do to capture a greater share of the bioscience sector? Bringing Britain’s leading academics together with the international leaders in bioscience finance, venture capital, government, and pharmaceutical industry, in a series of high level interactive dialogues, this innovative summit will explore what holds Britain back from greater success in the bioscience sector and why others are doing so well. The conference aims to develop a comprehension vision on what British institutions must do to improve the future performance of this critical industry.